National Institute of Oncology, Hungary
rate. Zoltan Marai
Observational investigation of participants who are given neoadjuvant treatment for invasive breast cancer. The scope of the study is to collect information on standardized treatment results, to explore the causes of dose modification and its effect on efficacy, to explore potential prognostic factors, and to explore the long-term side effects of different treatment modalities.
Breast Cancer
Grind it into fine powder
Goserelin
Letrozole 2.5Mg Tab
Epirubicin
cyclophosphamide
Docetaxel
paclitaxel
trastuzumab
pertuzumab
Capecitabine
The purpose of the study is based on the uniform application of international guidelines in Hungarian conditions. The standardized circumstances may lead to optimization of neoadjuvant therapy, it may facilitate subsequent data analysis, provide a basis for prospective clinical questions, and demonstrate improvement in pathologic complete remission (pCR) and overall survival (OS) compared to historical control. It may make possible to collect real-life data on each therapeutic option: efficacy, side effects, dose reduction, dose intensity, long-term consequences. The main scope is to collect prospective data to explore prognostic and predictive factors. The auxiliary aim is the assessment and comparison of quality of life during specific treatments and their side effects.}}
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Official Title : | Neoadjuvant Treatment of Breast Cancer - a Prospective Observational Study, PANnon ONCology (PANONC) Group Non-commercial Clinical Trial |
Actual Study Start Date : | March 2022 |
Estimated Primary Completion Date : | March 2023 |
Estimated Study Completion Date : | December 2031 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 100 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
National Institute of Oncology
Budapest, Hungary, 1122